Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy.
Autor: | Toussaint L; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus N, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus N, Denmark. Electronic address: lautou@rm.dk., Matysiak W; University of Groningen, University Medical Centre Groningen, Department of Radiation Oncology, Groningen, the Netherlands., Alapetite C; Institut Curie, Department of Radiation Oncology & Proton Centre, Paris, France., Aristu J; Clínica Universidad de Navarra, Proton Therapy Unit, Madrid, Spain., Bannink-Gawryszuk A; University of Groningen, University Medical Centre Groningen, Department of Radiation Oncology, Groningen, the Netherlands., Bolle S; Institut Curie, Department of Radiation Oncology & Proton Centre, Paris, France; Institut Gustave Roussy, Department of Radiation Oncology, Villejuif, France; Centro de Protonterapia Quironsalud, Madrid, Spain., Bolsi A; Paul Scherrer Institute, Centre for Proton Therapy, ETH Domain, Villigen, Switzerland., Calvo F; Clínica Universidad de Navarra, Proton Therapy Unit, Madrid, Spain., Cerron Campoo F; Centro de Protonterapia Quironsalud, Madrid, Spain., Charlwood F; University of Manchester, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom., Demoor-Goldschmidt C; Centre Regional Francois Baclesse, Department of Radiation Oncology, Caen, France; Angers University Hospital, Department of Paediatric Oncology, Angers, France., Doyen J; Centre Antoine Lacassagne, Department of Radiation Oncology, Nice, France., Drosik-Rutowicz K; National Research Institute of Oncology Kraków/Gliwice branch, Department of Radiation Oncology, Kraków, Poland., Dutheil P; Centre Regional Francois Baclesse, Department of Radiation Oncology, Caen, France., Embring A; Karolinska University Hospital, Department of Radiotherapy, Stockholm, Sweden., Engellau J; Skåne University Hospital, Hematology, Oncology and Radiation Physics, Lund, Sweden., Goedgebeur A; PARTICLE Proton Therapy Centre University Hospital Leuven, Department of Radiation Oncology, Leuven, Belgium., Goudjil F; Institut Curie, Department of Radiation Oncology & Proton Centre, Paris, France., Harrabi S; Heidelberg Ion Beam Therapy Centre, University Hospital Heidelberg, Department of Radiation Oncology, Heidelberg, Germany., Kopec R; Institute of Nuclear Physics, Polish Academy of Sciences, Kraków, Poland., Kristensen I; Skåne University Hospital, Hematology, Oncology and Radiation Physics, Lund, Sweden., Lægsdmand P; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus N, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus N, Denmark., Lütgendorf-Caucig C; MedAustron Ion Therapy Centre, Department of Radiation Oncology, Wiener Neustadt, Austria., Meijers A; Paul Scherrer Institute, Centre for Proton Therapy, ETH Domain, Villigen, Switzerland., Mirandola A; Radiation Oncology Unit, Clinical Department, National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy., Missohou F; Centre Regional Francois Baclesse, Department of Radiation Oncology, Caen, France., Montero Feijoo M; Centro de Protonterapia Quironsalud, Madrid, Spain., Muren LP; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus N, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus N, Denmark., Ondrova B; Proton Therapy Centre Czech, Department of Radiation Oncology, Prague, Czech Republic., Orlandi E; Radiation Oncology Unit, Clinical Department, National Centre for Oncological Hadrontherapy (CNAO), Pavia, Italy; University of Pavia, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, Pavia, Italy., Pettersson E; Sahlgrenska University Hospital, Department of Therapeutic Radiation Physics, Medical Physics and Biomedical Engineering, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Department of Medical Radiation Sciences, Gothenburg, Sweden., Pica A; Paul Scherrer Institute, Centre for Proton Therapy, ETH Domain, Villigen, Switzerland., Plaude S; West German Proton Therapy Centre Essen (WPE), Essen University Hospital, Essen, Germany., Righetto R; Hospital S. Chiara, APSS, Medical Physics Unit, Trento, Italy., Rombi B; Trento Proton Therapy Centre,epartment of Radiation Oncology, APSS Trento, Italy., Timmermann B; West German Proton Therapy Centre Essen (WPE), Essen University Hospital, Essen, Germany; Department of Particle Therapy, University Hospital Essen, Essen, Germany; West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Essen, Germany., Van Beek K; PARTICLE Proton Therapy Centre University Hospital Leuven, Department of Radiation Oncology, Leuven, Belgium., Vela A; Centre Regional Francois Baclesse, Department of Radiation Oncology, Caen, France., Vennarini S; Paediatric Radiotherapy Unit, IRCCS Foundation Institute of Cancer, Milano, Italy., Vestergaard A; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus N, Denmark., Vidal M; Centre Antoine Lacassagne, Department of Radiation Oncology, Nice, France., Vondracek V; Proton Therapy Centre Czech, Department of Radiation Oncology, Prague, Czech Republic., Weber DC; Paul Scherrer Institute, Centre for Proton Therapy, ETH Domain, Villigen, Switzerland., Whitfield G; University of Manchester, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; University of Manchester, Royal Manchester Children's Hospital, The Children's Brain Tumour Research Network, Manchester, United Kingdom., Zimmerman J; Karolinska University Hospital, Department of Radiotherapy Physics and Engineering, Stockholm, Sweden., Maduro JH; University of Groningen, University Medical Centre Groningen, Department of Radiation Oncology, Groningen, the Netherlands., Lassen-Ramshad Y; Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus N, Denmark. |
---|---|
Jazyk: | angličtina |
Zdroj: | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Sep; Vol. 198, pp. 110414. Date of Electronic Publication: 2024 Jun 26. |
DOI: | 10.1016/j.radonc.2024.110414 |
Abstrakt: | Background and Purpose: As no guidelines for pencil beam scanning (PBS) proton therapy (PT) of paediatric posterior fossa (PF) tumours exist to date, this study investigated planning techniques across European PT centres, with special considerations for brainstem and spinal cord sparing. Materials and Methods: A survey and a treatment planning comparison were initiated across nineteen European PBS-PT centres treating paediatric patients. The survey assessed all aspects of the treatment chain, including but not limited to delineations, dose constraints and treatment planning. Each centre planned two PF tumour cases for focal irradiation, according to their own clinical practice but based on common delineations. The prescription dose was 54 Gy(RBE) for Case 1 and 59.4 Gy(RBE) for Case 2. For both cases, planning strategies and relevant dose metrics were compared. Results: Seventeen (89 %) centres answered the survey, and sixteen (80 %) participated in the treatment planning comparison. In the survey, thirteen (68 %) centres reported using the European Particle Therapy Network definition for brainstem delineation. In the treatment planning study, while most centres used three beam directions, their configurations varied widely across centres. Large variations were also seen in brainstem doses, with a brainstem near maximum dose (D2%) ranging from 52.7 Gy(RBE) to 55.7 Gy(RBE) (Case 1), and from 56.8 Gy(RBE) to 60.9 Gy(RBE) (Case 2). Conclusion: This study assessed the European PBS-PT planning of paediatric PF tumours. Agreement was achieved in e.g. delineation-practice, while wider variations were observed in planning approach and consequently dose to organs at risk. Collaboration between centres is still ongoing, striving towards common guidelines. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |